With the recent discovery of HER2-targeted therapy’s efficacy in patients with gastrointestinal cancers, the community oncology team is further challenged to keep abreast of the most recent data.  That in concert with the new trial findings of patients with either GEJ or GC who respond to HER2-targeted antibody-drug conjugate therapy in spite of HER2-low levels of expression continue to challenge the community oncologist. The application of this new data can be supported through the understanding and use of practice guidelines which will be reviewed along with their supporting clinical trial findings. Finally, the knowledge to both recognize and treat adverse events associated with antibody-drug conjugates in the gastrointestinal cancer population is essential for the optimal care of these patients.

RELEASED DATE: June 19, 2024
EXPIRATION DATE: June 19, 2025